Pfizer on Thursday said it is moving forward with a once-daily weight loss pill, danuglipron, after getting promising data from an early-stage trial, a milestone for the pharma giant hoping to enter the lucrative obesity drug market and compete with popular weight loss injections Wegovy and Zepbound.
Pfizer said it was moving forward with oral weight loss pill danuglipron.
Pfizer said it had evaluated several once-daily formulations of danuglipron and selected its preferred one to move forward to mid-stage trials with.
The pharma giant said it had seen “encouraging” data from an ongoing early-stage trial and had identified the candidate with “the most favorable profile.”
Pfizer shares were up nearly 2% during premarket trading after the announcement.
This is a developing story.